RPTX

Repare Therapeutics Inc

Add to Watchlist

Advanced Chart

1.370

+0.050(+3.790%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

1.390

Open

1.310

VWAP

1.33

Vol

318.32K

Mkt Cap

58.66M

Low

1.280

Amount

421.92K

EV/EBITDA(TTM)

Total Shares

42.45M

-94.98M

EV/OCF(TTM)

P/S(TTM)

1.09

Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

2.73M

-79.05%

-0.650

-316.67%

1.67M

-96.82%

-0.560

-31.71%

-0.490

-36.73%

Estimates Revision

The market is revising Downward the revenue expectations for Repare Therapeutics Inc. (RPTX) for FY2025, with the revenue forecasts being adjusted by -27.51% over the past three months. During the same period, the stock price has changed by 15.13%.

Revenue Estimates for FY2025

Revise Downward

-27.51%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-32.42%

In Past 3 Month

Stock Price

Go Up

+15.13%

In Past 3 Month

3 Analyst Rating

264.96% Upside

Wall Street analysts forecast RPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RPTX is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

264.96% Upside

Current: 1.370

Low

5.00

Averages

5.00

High

5.00

264.96% Upside

Current: 1.370

Low

5.00

Averages

5.00

High

5.00

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$10 → $5

2025-03-07

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10 → $5

2025-03-07

Maintains

Strong Buy

Reason

Stifel

Benjamin Burnett

Strong Buy

Maintains

$9 → $4

2024-12-13

Reason

Stifel

Benjamin Burnett

Price Target

$9 → $4

2024-12-13

Maintains

Strong Buy

Reason

Stifel analyst Benjamin Burnett lowered the firm's price target on Repare Therapeutics to $4 from $9 and keeps a Buy rating on the shares after updated results for camonsertib plus lunresertib came in below expectations. The firm expects the debate after the data to focus on the likelihood of success in endometrial cancer and for continued scrutiny of the balance sheet, the analyst tells investors.

LifeSci Capital

Charles Zhu

Buy

Hold

Downgrades

n/a

2024-12-13

Reason

LifeSci Capital

Charles Zhu

Price Target

n/a

2024-12-13

Downgrades

Buy

Hold

Reason

LifeSci Capital downgraded Repare Therapeutics to Market Perform from Outperform.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$10

2024-11-08

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10

2024-11-08

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$10

2024-10-24

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10

2024-10-24

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$10

2024-09-23

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$10

2024-09-23

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Repare Therapeutics Inc (RPTX.O) is -0.64, compared to its 5-year average forward P/E of -7.01. For a more detailed relative valuation and DCF analysis to assess Repare Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.01

Current PE

-0.64

Overvalued PE

-0.73

Undervalued PE

-13.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.94

Current EV/EBITDA

0.78

Overvalued EV/EBITDA

0.80

Undervalued EV/EBITDA

-8.67

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

102.92

Current PS

7.97

Overvalued PS

251.24

Undervalued PS

-45.41

Financials

Annual

Quarterly

FY2024Q4

YoY :

-100.00%

0.00

Total Revenue

FY2024Q4

YoY :

-0.23%

-30.80M

Operating Profit

FY2024Q4

YoY :

+2.29%

-28.67M

Net Income after Tax

FY2024Q4

YoY :

-0.00%

-0.67

EPS - Diluted

FY2024Q4

YoY :

-4.31%

-27.32M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

-43.38%

-142.95

FCF Margin - %

FY2024Q4

YoY :

-26.28%

-158.37

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 129.93% over the last month.

Sold

0-3

Months

42.5K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

26.5K

Volume

6-9

Months

0.0

Volume

0-12

Months

3.7M

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 129.93% over the last month.

Sold

0-3

Months

42.5K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

RPTX News & Events

Events Timeline

2025-03-31 (ET)

2025-03-31

16:43:31

Repare Therapeutics CEO Lloyd Segal resigns, Steve Forte succeeds

2025-03-03 (ET)

2025-03-03

07:20:36

Repare Therapeutics reports Q4 EPS (67c), consensus (79c)

2025-01-09 (ET)

2025-01-09

15:13:44

Repare Therapeutics announces portfolio reprioritization, partnering initiatives

News

5.0

04-12Benzinga

Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics

5.0

04-12Benzinga

Cathie Wood's Ark Invest Offloads UiPath, Prime Medicine, And Repare Therapeutics

5.0

04-05Benzinga

Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox

People Also Watch

STOK

Stoke Therapeutics Inc

Montana Technologies Corp

Flushing Financial Corp

Northfield Bancorp Inc

Gladstone Investment Corp

13.750

USD

-1.08%

FAQ

What is Repare Therapeutics Inc (RPTX) stock price today?

The current price of RPTX is 1.37 USD — it has increased 3.79 % in the last trading day.

RPTX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

RPTX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Repare Therapeutics Inc (RPTX) stock price today?

What is Repare Therapeutics Inc (RPTX)'s business?

What is the price predicton of RPTX Stock?

What is Repare Therapeutics Inc (RPTX)'s revenue for the last quarter?

What is Repare Therapeutics Inc (RPTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Repare Therapeutics Inc (RPTX)'s fundamentals?

How many employees does Repare Therapeutics Inc (RPTX). have?

What is Repare Therapeutics Inc (RPTX) market cap?